Author Archive: Celia Economides

Celia is the Manager of Investor Relations & Business Development at BIO. In this role, she is responsible for all outreach to the investment community and for aiding emerging companies with business development practices. She is responsible for organizing the programming for several biotech investor conferences, and for providing industry research to the organization that is used in BIO’s lobbying and advocacy efforts. Prior to joining BIO, Celia was a biotech analyst for Visium Asset Management, LLC, focusing on companies developing neurological compounds. Previously, Celia worked with Guidepoint Global, LLC serving in multiple roles, but most prominently as the Director of Healthcare Events, where she interfaced with institutional healthcare investors and thought leaders in the medical community. Prior to completing her master’s degree, Celia worked as a research coordinator for neurological clinical trials addressing Alzheimer’s and epilepsy at Columbia University. She received a master’s of public health from Columbia University’s Mailman School of Public Health and a bachelor’s degree from McGill University.

Latest Posts

LifeCycle Pharma announces Phase 2 results for liver transplant patients study

LifeCycle Pharma A/S (CSE:LCP) announced positive results from a 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug to prevent rejection after organ transplantation. These new data demonstrated that LCP-Tacro tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,